Immuno-Oncology Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET OVERVIEW

Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which boosts the body's natural defenses to resist the growth of cancer. This therapy utilizes constituents made by the body or in a research laboratory to reestablish or improve the immune system function. Immuno-oncology is a cutting-edge cancer research technique that aims to use the body's own immune system to fight cancer cells. The world is currently at the forefront of this field, with many substances under development for use in a variety of malignancies, as well as an approved immuno-oncology drug which is still being investigated for novel applications.

MARKET SCOPE

The "Global Immuno-Oncology Drugs Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the immuno-oncology drugs market with detailed market segmentation by drug type, therapeutic application and end user. The report provides key statistics on the market status of the leading immuno-oncology drugs market players and offers key trends and opportunities in the market.MARKET SEGMENTATION

•   Based on drug type the market is segmented as, immune checkpoint inhibitors, monoclonal antibodies, cytokine based immunotherapy, cancer vaccines, Car-T cell therapy.
  
•   Based on therapeutic application the market is segmented as, melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, others.
  
•   Based on end user the market is segmented as, hospitals, clinics, ambulatory surgical centers.
  

MARKET DYNAMICS
Drivers:

•   Growing prevalence of cancers across the globe is the key driving factor for the market growth.
  
•   Rising adoption of immuno therapy drugs to manage malignancies.
  
•   Extensive R&D activities to develop and lauch more targeted therapies for management of cancers and malignancies.
  

Restraints:

•   However, high cost associated with the therapy is expected to restrain market growth during the forecast period.
  

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The immuno-oncology drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the immuno-oncology drugs market in these regions.

IMPACT OF COVID-19 ON IMMUNO-ONCOLOGY DRUGS MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

Immuno-Oncology Drugs Market Report Analysis

Immuno-Oncology Drugs Market

• 
  CAGR (2023 - 2031)

  XX%
• Market Size 2023
  US$ XX Million
• Market Size 2031
  US$ XX Million

Report Coverage

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope

• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis

• Industry landscape and competition analysis & recent developments
• Detailed company profiles

• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments

Key Players

• Amgen, Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• Lilly
• Sanofi
• F. Hoffmann-La Roche
• Novartis AG
• AbbVie, Inc.
• Pfizer Inc.

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

By Drug Type

• Immune Checkpoint Inhibitors
• Monoclonal Antibodies
• Cytokine Based Immunotherapy
• Cancer Vaccines
• CAR-T Cell Therapy

By Therapeutic Application

• Melanoma
• Lung Cancer
• Blood Cancer
• Renal Cell Carcinoma
• Prostate Cancer
• Bladder Cancer

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers

MARKET PLAYERS

The report covers key developments in the immuno-oncology drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from immuno-oncology drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for immuno-oncology drugs in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the immuno-oncology drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  Amgen, Inc.

  AstraZeneca

  Bristol-Myers Squibb Company

  Lilly

  Sanofi

  F. Hoffmann-La Roche

  Novartis AG

  AbbVie, Inc.

  Pfizer Inc.

  Merck KGaA,
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Immuno-Oncology Drugs Market Report Scope

Report Attribute	Details
Market size in 2023	US$ XX Million
Market Size by 2031	US$ XX Million
Global CAGR (2023 - 2031)	XX%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Drug Type Immune Checkpoint Inhibitors Monoclonal Antibodies Cytokine Based Immunotherapy Cancer Vaccines CAR-T Cell Therapy By Therapeutic Application Melanoma Lung Cancer Blood Cancer Renal Cell Carcinoma Prostate Cancer Bladder Cancer By End User Hospitals Clinics Ambulatory Surgical Centers
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Amgen, Inc. AstraZeneca Bristol-Myers Squibb Company Lilly Sanofi F. Hoffmann-La Roche Novartis AG AbbVie, Inc. Pfizer Inc.